3-[4-(2-pyrazinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[4-(2-pyrazinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate
• 英文别名: 3-(4-pyrazin-2-ylpiperazin-1-yl)propyl N-(2-ethoxyphenyl)carbamate
• 化学式: C₂₀H₂₇N₅O₃
• 分子量: 385.466
• InChiKey: BPDWDUJPWWHGSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 (2S,3S,4S,5R,6S)-6-[[(4R,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 、 1-(2,5-二甲基苯基)哌嗪 在 三氟乙酸 作用下， 反应 2.0h， 生成 3-[4-(4-pyridinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-pyrimidinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(4-pyrimidinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(3-pyridazinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-pyrazinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-pyridinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-methylphenyl)piperazino]propyl N-(2-ethoxyphenyl)carbamate 、 3-[4-(4-methylphenyl)piperazino]propyl N-(2-ethoxyphenyl)carbamate 、 3-[4-(3-methylphenyl)piperazino]propyl N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-chlorophenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-fluorophenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(6-chloro-3-pyridazinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(6-methyl-3-pyridazinyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2-methoxyphenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(4-fluorophenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(4-chlorophenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(3-chlorophenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(3-methoxyphenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-(2,5-dimethylphenyl)piperazino]propyl-N-(2-ethoxyphenyl)carbamate 、 3-[4-[3-(trifluoromethyl)phenyl]piperazino]propyl-N-(2-ethoxyphenyl)carbamate
  参考文献：
  名称：

  Aryl carbamate derivatives, preperation and use thereof

  摘要：

  本发明涉及新化合物，其制备和使用，特别是在治疗方面。更具体地说，它涉及从芳基氨基甲酸酯衍生的化合物，其制备和使用，特别是在人类和动物健康领域。根据本发明的化合物首选是5-HT4受体的血清素受体配体，因此可以在治疗或预防涉及5-HT4受体的任何疾病的治疗中使用。本发明还涉及包含此类化合物的药物组合物，其制备和使用以及使用该化合物的治疗方法。

  公开号：

  US20040058933A1

文献信息

• US7238693B2
  申请人：——

  公开号：US7238693B2

  公开（公告）日：2007-07-03